Cargando…

Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study

The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 202...

Descripción completa

Detalles Bibliográficos
Autores principales: GULER, OZAN CEM, OYMAK, EZGI, YAZICI, GOZDE, AKAGUNDUZ, OZLEM OZKAYA, CETINAYAK, OGUZ, ERPOLAT, PETEK, AKSOY, ATIL, DUZOVA, MURSEL, YILDIRIM, BERNA AKKUS, KURT, MERAL, CANYILMAZ, EMINE, YAVAS, GULER, AKYUREK, SERAP, OKSUZ, DIDEM COLPAN, SAGLAM, ESRA KAYTAN, CELIK, OMUR KARAKOYUN, OZYAR, ENIS, CENGIZ, MUSTAFA, ONAL, CEM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229304/
https://www.ncbi.nlm.nih.gov/pubmed/37305394
http://dx.doi.org/10.32604/or.2023.028840
_version_ 1785051208798437376
author GULER, OZAN CEM
OYMAK, EZGI
YAZICI, GOZDE
AKAGUNDUZ, OZLEM OZKAYA
CETINAYAK, OGUZ
ERPOLAT, PETEK
AKSOY, ATIL
DUZOVA, MURSEL
YILDIRIM, BERNA AKKUS
KURT, MERAL
CANYILMAZ, EMINE
YAVAS, GULER
AKYUREK, SERAP
OKSUZ, DIDEM COLPAN
SAGLAM, ESRA KAYTAN
CELIK, OMUR KARAKOYUN
OZYAR, ENIS
CENGIZ, MUSTAFA
ONAL, CEM
author_facet GULER, OZAN CEM
OYMAK, EZGI
YAZICI, GOZDE
AKAGUNDUZ, OZLEM OZKAYA
CETINAYAK, OGUZ
ERPOLAT, PETEK
AKSOY, ATIL
DUZOVA, MURSEL
YILDIRIM, BERNA AKKUS
KURT, MERAL
CANYILMAZ, EMINE
YAVAS, GULER
AKYUREK, SERAP
OKSUZ, DIDEM COLPAN
SAGLAM, ESRA KAYTAN
CELIK, OMUR KARAKOYUN
OZYAR, ENIS
CENGIZ, MUSTAFA
ONAL, CEM
author_sort GULER, OZAN CEM
collection PubMed
description The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients’ performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78–7.00, p < 0.001) and PFS (HR = 4.28, 95% CI, 2.79–6.58, p < 0.001), whereas poor performance score was a predictor for worse LRFS (HR = 1.83, 95% CI, 1.12–2.98, p = 0.02) in multivariable analysis. Fifty-two patients (29.7%) experienced grade II or higher toxicity. In this multicenter study, we demonstrated that definitive CRT is a safe and effective treatment for patients with CEC. Higher radiation doses were found to have no effect on treatment outcomes, but a better response to treatment and a better patient performance status did.
format Online
Article
Text
id pubmed-10229304
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tech Science Press
record_format MEDLINE/PubMed
spelling pubmed-102293042023-06-10 Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study GULER, OZAN CEM OYMAK, EZGI YAZICI, GOZDE AKAGUNDUZ, OZLEM OZKAYA CETINAYAK, OGUZ ERPOLAT, PETEK AKSOY, ATIL DUZOVA, MURSEL YILDIRIM, BERNA AKKUS KURT, MERAL CANYILMAZ, EMINE YAVAS, GULER AKYUREK, SERAP OKSUZ, DIDEM COLPAN SAGLAM, ESRA KAYTAN CELIK, OMUR KARAKOYUN OZYAR, ENIS CENGIZ, MUSTAFA ONAL, CEM Oncol Res Article The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients’ performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78–7.00, p < 0.001) and PFS (HR = 4.28, 95% CI, 2.79–6.58, p < 0.001), whereas poor performance score was a predictor for worse LRFS (HR = 1.83, 95% CI, 1.12–2.98, p = 0.02) in multivariable analysis. Fifty-two patients (29.7%) experienced grade II or higher toxicity. In this multicenter study, we demonstrated that definitive CRT is a safe and effective treatment for patients with CEC. Higher radiation doses were found to have no effect on treatment outcomes, but a better response to treatment and a better patient performance status did. Tech Science Press 2023-05-24 /pmc/articles/PMC10229304/ /pubmed/37305394 http://dx.doi.org/10.32604/or.2023.028840 Text en © 2023 Guler et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
GULER, OZAN CEM
OYMAK, EZGI
YAZICI, GOZDE
AKAGUNDUZ, OZLEM OZKAYA
CETINAYAK, OGUZ
ERPOLAT, PETEK
AKSOY, ATIL
DUZOVA, MURSEL
YILDIRIM, BERNA AKKUS
KURT, MERAL
CANYILMAZ, EMINE
YAVAS, GULER
AKYUREK, SERAP
OKSUZ, DIDEM COLPAN
SAGLAM, ESRA KAYTAN
CELIK, OMUR KARAKOYUN
OZYAR, ENIS
CENGIZ, MUSTAFA
ONAL, CEM
Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
title Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
title_full Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
title_fullStr Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
title_full_unstemmed Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
title_short Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study
title_sort multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: trod 01-005 study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229304/
https://www.ncbi.nlm.nih.gov/pubmed/37305394
http://dx.doi.org/10.32604/or.2023.028840
work_keys_str_mv AT gulerozancem multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT oymakezgi multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT yazicigozde multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT akagunduzozlemozkaya multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT cetinayakoguz multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT erpolatpetek multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT aksoyatil multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT duzovamursel multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT yildirimbernaakkus multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT kurtmeral multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT canyilmazemine multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT yavasguler multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT akyurekserap multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT oksuzdidemcolpan multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT saglamesrakaytan multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT celikomurkarakoyun multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT ozyarenis multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT cengizmustafa multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study
AT onalcem multiinstitutionalanalysisofcervicalesophagealcarcinomapatientstreatedwithdefinitivechemoradiotherapytrod01005study